Stay updated with breaking news from Ian Flitcroft. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Time spent outdoors is the best defence against rising rates of short-sightedness, but scientists are searching for other ways to reverse the troubling trend. Time spent outdoors is the best defence against rising rates of short-sightedness, but scientists are searching for other ways to reverse the troubling trend.
Dopavision has announced positive topline results from a proof-of-concept trial of MyopiaX, a noninvasive photobiomodulation intervention designed to slow myopia progression in children.“The 6-month outcomes represent a significant step in the clinical development of MyopiaX,” Ian Flitcroft, PhD, FRCOphth, coordinating investigator of the MyopiaX-1 trial, said in a company press
Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX's excellent safety and tolerability profile with no untoward safety events. Novel Approach: Dopavision's
Findings will be shared at Ophthalmology Futures Forums, the WSPOS Sub-Specialty Day 2023, and the ESCRS iNovation Day 2023 in Austria.
Clinical trial suggests low-dose atropine is an effective myopia treatment. The results of a new clinical trial suggest that the first drug therapy to slow the progression of nearsightedness in kids could be on the horizon. The three-year study found that a daily drop in each eye of a low dose o